NAD+, NMN and Vitamin B12

Overview

The NAD+, NMN and vitamin B12 blend is a fixed-ratio research combination of three compounds tied to cellular energy metabolism: nicotinamide adenine dinucleotide (NAD+), a redox coenzyme; nicotinamide mononucleotide (NMN), a direct biosynthetic precursor of NAD+; and vitamin B12 (cobalamin), an essential water-soluble vitamin. In the controlled-dose format stocked by research suppliers, a single vial contains 500 mg of NAD+, 500 mg of NMN, and 8 mg of vitamin B12.

Unlike the two-part NAD+ and B12 blend, this version splits the NAD+ content with NMN. The intent reflected in the formulation is to combine NAD+ itself with a precursor that cells can convert to NAD+, alongside a B vitamin. NMN has been the subject of a growing number of human trials in recent years, while NAD+ infusion research remains limited and vitamin B12 has a long, well-established clinical record. The three-part combination as a single product has not been evaluated in any controlled study.

This profile summarizes the published research on each component separately and is provided strictly as educational reference material. The blend is sold for laboratory research use only and is not a medicine, supplement, or treatment.

Mechanism of Action

The three components relate to cellular energy in different ways. NAD+ and NMN sit on the same pathway; vitamin B12 is separate.

NAD+: the redox coenzyme

NAD+ is an electron carrier in central energy metabolism. It accepts electrons during glycolysis, fatty acid oxidation, and the citric acid cycle, becoming NADH, which feeds the mitochondrial electron transport chain that produces ATP. NAD+ is also consumed as a substrate by the sirtuins, the PARP DNA-repair enzymes, and CD38, so the cell must continually resynthesize it.

NMN: an NAD+ precursor

NMN (beta-nicotinamide mononucleotide) is a direct precursor in the NAD+ salvage pathway. The enzyme NMNAT converts NMN to NAD+ in a single step. Supplying NMN is therefore one of the strategies researchers use to attempt to raise intracellular NAD+ levels, on the reasoning that NAD+ pools decline in some tissues with age. How efficiently orally administered NMN reaches cells and is converted to NAD+ in humans is still an active research question.

Vitamin B12: a separate cofactor

Vitamin B12 does not act on the NAD+ pathway. As methylcobalamin it is a cofactor for methionine synthase, linking it to homocysteine and folate-dependent methylation chemistry; as adenosylcobalamin it supports the mitochondrial enzyme methylmalonyl-CoA mutase. Its inclusion in the blend reflects a separate interest in methylation and B-vitamin status rather than a shared mechanism with NAD+ and NMN.

Research Summary

Of the three components, NMN has the most active recent human research. Several randomized, double-blind, placebo-controlled trials have tested oral NMN, generally at doses from 250 mg to 1,250 mg per day for periods of several weeks. These studies have consistently reported that NMN was safe and well tolerated and that it raised blood NAD+ levels. Functional outcomes have been more mixed: individual trials have reported signals such as improved aerobic capacity in amateur runners and changes in measures like blood pressure or walking performance, while reviewers caution that effects on age-related physical decline remain inconsistent across studies.

NAD+ administered directly, typically by intravenous infusion, has a much thinner evidence base. A pilot study tracked the plasma and urinary NAD+ metabolome during a six-hour infusion, and a 2023 systematic review concluded that human efficacy data for NAD and its precursors remain limited. Vitamin B12 is supported by a large, mature clinical literature centered on the diagnosis and treatment of deficiency; injectable cyanocobalamin is an FDA-approved treatment for B12 deficiency and pernicious anemia.

No published study has evaluated the NAD+, NMN and B12 combination as a single fixed-ratio product. Statements about what the blend does are inferences from three separate literatures, not findings about the blend itself.

Dosing in Published Research

Published NMN trials have used oral doses generally in the range of 250 mg to 1,250 mg per day, taken for periods of a few weeks to several months, in studies designed to assess safety and to measure blood NAD+ responses. Those figures describe the doses tested in specific research protocols; they are not a recommended intake and were not established for the injectable or blended forms.

For vitamin B12, the FDA-approved cyanocobalamin injection label describes a deficiency-treatment regimen of 100 mcg by intramuscular or deep subcutaneous injection daily for six to seven days, then tapering, with lifelong monthly 100 mcg maintenance for pernicious anemia. For NAD+ itself there is no approved medicine and no labeled dose; the few human studies used multi-hour intravenous infusions to study NAD+ metabolism rather than to set a standard dose.

Safety and Side Effects

The safety considerations for the blend are those of its three components.

NMN

Across the published randomized trials, oral NMN has generally been reported as safe and well tolerated at the doses tested, with no serious adverse events consistently attributed to it. Reported effects have been mild and infrequent. However, the trials are relatively short and modest in size, and long-term safety has not been established. The safety of NMN given by injection, as opposed to orally, has not been characterized in published trials.

NAD+

Intravenous NAD+ is most consistently associated with infusion-related discomfort, including flushing, chest or abdominal tightness, nausea, lightheadedness, and cramping when infused too quickly; slowing the infusion generally reduces these effects. Some adverse effects are attributed to supraphysiologic extracellular NAD+ and its pro-inflammatory activity. Long-term safety data are lacking.

Vitamin B12

Vitamin B12 has a strong safety record. It is water-soluble, has no established tolerable upper intake level, and excess is largely excreted. Uncommon adverse effects include injection-site reactions, rare cobalamin hypersensitivity, and acneiform skin eruptions at high doses. High-dose B12 can correct the anemia of a combined B12-and-folate deficiency while underlying neurological damage continues, which is one reason deficiency is managed under medical supervision.

The blend

Because the three-part combination has not been formally studied, its interactions and combined safety profile are unknown. It is sold strictly for in-vitro laboratory research and is not intended for human or veterinary use.

Current Research Status

The three components have markedly different regulatory and research positions. Injectable cyanocobalamin (vitamin B12) is an FDA-approved prescription medicine for B12 deficiency and pernicious anemia. NAD+ is not an approved drug; it is sold as a research compound and offered through wellness clinics as an intravenous infusion outside any approved indication.

NMN occupies a contested regulatory space in the United States. In November 2022 the FDA took the position that NMN could not be marketed as a dietary supplement because it had been authorized for investigation as a new drug, a determination connected to clinical investigation of an NMN drug candidate. That position was challenged by the supplement industry, and the regulatory status of NMN has remained unsettled and subject to ongoing dispute since then.

The fixed NAD+, NMN and B12 blend is not an approved product of any kind and has never been studied as a combination. It is marketed for laboratory and research use only and should be treated as an experimental research material rather than a therapy. For factual information, the separate literature on each component is the appropriate source.

Frequently Asked Questions